1.1Ubiquinone supports electron transfer
A lipid phase carries ubiquinone, and an aqueous phase carries trigonelline. In the inner mitochondrial membrane, ubiquinone accepts electrons from complexes I and II and transfers them to complex III.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A lipid phase carries ubiquinone, and an aqueous phase carries trigonelline. In the inner mitochondrial membrane, ubiquinone accepts electrons from complexes I and II and transfers them to complex III.
The formulation combines riboflavin and trigonelline in a dry powder. Cells convert riboflavin to flavin mononucleotide and flavin adenine dinucleotide, which serve as redox cofactors in respiratory complexes I and II, respectively.
L-carnitine and trigonelline dissolve in water to form an oral solution. The mitochondrial carnitine shuttle transfers long-chain fatty acyl groups into the matrix as acylcarnitines and regenerates fatty acyl-CoA for beta oxidation.
A dry capsule combines nicotinamide with micronized urolithin powder. The NAD salvage pathway converts nicotinamide to nicotinamide mononucleotide and then to NAD+, a cofactor for mitochondrial fuel oxidation.
A tablet combines nicotinic acid and urolithin with microcrystalline cellulose. Cells convert nicotinic acid to nicotinic acid mononucleotide, then to nicotinic acid adenine dinucleotide, and finally to NAD+.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A laboratory training kit contains a dry mixture of urolithin A and trigonelline with an assigned mass for each analyte. The operator extracts a weighed portion with aqueous methanol and divides the filtered extract between reversed-phase and hydrophilic interaction liquid chromatography methods. The operator calculates the recovery of each analyte from its assigned mass and measured concentration.
A two-component test blend uses urolithin B in place of urolithin A and retains trigonelline. The operator weighs both powders on a dry-mass basis and mixes them by tumbling in a sealed vessel. Separate chromatographic assays measure the content of each component in samples drawn from several locations in the blend.
Five bench batches each contain 10 grams of combined urolithin A and trigonelline on a dry-mass basis. The urolithin A to trigonelline mass ratios are 1:9, 1:3, 1:1, 3:1, and 9:1. The operator tumble-mixes each batch for 15 minutes at 30 revolutions per minute and assays three subsamples from each batch.
Separate loss-in-weight screw feeders meter urolithin A and trigonelline into a continuous paddle blender. The feeder setpoints establish the mass ratio, and the sum of the feed rates establishes the blend throughput. A timed sampler collects portions from the discharge stream for separate assays of both components.
A roller compactor processes urolithin A and trigonelline in separate runs, and a mill breaks each compacted ribbon into granules. Two dosing stations on a capsule filler deposit measured quantities of the respective granules into the same capsule body before the closing station seats the cap. Assays on individual capsules measure the fill content of each component.
A controller reads a balance under a receiving vessel and records the mass added by the urolithin A feeder and the trigonelline feeder in sequence. After each addition, the controller waits for a stable reading and calculates the delivered mass from the change in vessel weight. The controller starts the mixer when both delivered masses are within 2 percent of their respective setpoints and flags the vessel for rework otherwise.
Micronized urolithin A forms the solid phase of an aqueous suspension. Polysorbate 80 wets the particles, and xanthan gum increases the viscosity of the liquid to slow settling.
Milled crystalline urolithin B is blended with microcrystalline cellulose. The dry blend fills a two-piece hydroxypropyl methylcellulose capsule.
Trigonelline in its zwitterionic form dissolves in purified water. A citrate buffer sets the pH of the aqueous formulation to 5.5.
Crystalline trigonelline hydrochloride is blended with mannitol and crospovidone before compression. Crospovidone promotes tablet breakup on contact with water, exposing the salt for dissolution.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Pharmaceutical composition comprising an effective amount of at least one urolithin chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof, and a pharmaceutically acceptable vehicle.A · US 2016/0279097 A1 · claim 29
As used herein, “trigonelline” is any compound comprising 1-methylpyridin-1-ium-3-carboxylate including, for example, any salt thereof (e.g., Chloride or Iodide salt) and/or a form in which the ring therein may be reduced.B · US 2022/0249453 A1 · ¶ 71
An empty cell means only that no passage was reproduced there.
Although some positive results were obtained, a compound both efficient and devoid of long term side-effects is still required.A · US 2016/0279097 A1 · ¶ 5
The present invention first relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D or a combination thereof intended for its use for the stimulation of insulin secretion, and to a composition comprising urolithin B, urolithin C, urolithin D or a combination thereof intended for its use for the treatment or the prevention of diabetes mellitus.A · US 2016/0279097 A1 · ¶ 1
Intracellular levels of NAD+ can be increased in cells and tissues to improve cell and tissue survival and/or or overall cell and tissue health.B · US 2022/0249453 A1 · ¶ 1
In an embodiment, the composition is selected from the group consisting of a food product, a food supplement, an oral nutritional supplement (ONS), a medical food, and combinations thereof.B · US 2022/0249453 A1 · ¶ 7
patent.fyi, US 2026/0355147 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355147/, SHA-256 e409ceb25545a86709e7d02d46194c247756d9d2b447a59c9d7ecf6a7a117368